Does CHORIOGONADOTROPIN ALFA Cause Product packaging quantity issue? 80 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 80 reports of Product packaging quantity issue have been filed in association with CHORIOGONADOTROPIN ALFA (Ovidrel). This represents 2.9% of all adverse event reports for CHORIOGONADOTROPIN ALFA.
80
Reports of Product packaging quantity issue with CHORIOGONADOTROPIN ALFA
2.9%
of all CHORIOGONADOTROPIN ALFA reports
0
Deaths
0
Hospitalizations
How Dangerous Is Product packaging quantity issue From CHORIOGONADOTROPIN ALFA?
Of the 80 reports.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CHORIOGONADOTROPIN ALFA. However, 80 reports have been filed with the FAERS database.
What Other Side Effects Does CHORIOGONADOTROPIN ALFA Cause?
Ovarian hyperstimulation syndrome (1,016)
Ascites (261)
No adverse event (200)
Abdominal pain (169)
Drug ineffective (161)
Abdominal distension (160)
Dyspnoea (144)
Off label use (139)
Nausea (113)
Product dose omission issue (100)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which CHORIOGONADOTROPIN ALFA Alternatives Have Lower Product packaging quantity issue Risk?
CHORIOGONADOTROPIN ALFA vs CIALIS
CHORIOGONADOTROPIN ALFA vs CICLESONIDE
CHORIOGONADOTROPIN ALFA vs CICLOPIROX
CHORIOGONADOTROPIN ALFA vs CICLOPIROX OLAMINE
CHORIOGONADOTROPIN ALFA vs CICLOSPORIN